Kaken Pharmaceuticals Files Application For Onychomycosis Drug
This article was originally published in PharmAsia News
Executive Summary
Kaken Pharmaceuticals announced Oct. 23 it has filed a new drug application in Japan for KP-103 (efinaconazole), a therapeutic agent for onychomycosis.